

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: The Yield Growth Corp. (the "Issuer").

Trading Symbol: BOSS

Number of Outstanding Listed Securities: 95,922,223 common shares (plus 50,041,945 common shares reserved for issuance in the form of 34,717,785 warrants, 1,707,332 special warrants and 13,616,828 options)

Date: September 1, 2019

Report on Business

- 1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.**

On August 1, 2019, the Issuer announced it had entered into a definitive agreement to provide a non-exclusive license for the worldwide rights to 8 hemp product topical formulas to Antler Retail Inc. ("Antler"). The 8 licensed formulas are intended to be launched in Antler's men's line for hair pomade, beard oil, shaving cream, deodorant and essential oil colognes.

On August 15, 2019, the Issuer announced it has entered into a distribution agreement with Antler for worldwide distribution rights to the Antler Real Men hemp product line. Antler also completed payment of \$800,000 to the Issuer on the previously announced licensing agreement for a non-exclusive perpetual license for the worldwide rights to 8 hemp product topical formulas created by the Issuer.

On August 19, 2019, the Issuer announced that its subsidiary, Urban Juve's, Ultra Hydrating Lip Balm with Hemp Oil can now be sold in the European market upon Urban Juve's Responsible Person In Europe, Birorius, having issued a compliance certificate for the product in accordance with EU regulations.

On August 27, 2019, the Issuer announced it has entered into a distribution and licensing agreement with 2699598 Ontario Corp. DBA Melorganics Hellas ("Melorganics") for European rights to 6 product formulas for CBD infusion for a fee of \$900,000. The Issuer has agreed to license to Melorganics, in perpetuity, the non-exclusive rights to formulas and know-how to manufacture and distribute CBD foot cream, CBD body oil, CBD muscle relief balm, CBD body exfoliant, CBD relief gel and CBD hand cream. The formulas may be developed by Melorganics into products infused with CBD and other cannabinoids and distributed throughout the European Union under one brand to be developed by Melorganics.

On August 29, 2019, the Issuer announced that it has entered into an exclusive distribution agreement through its wholly owned subsidiary, Urban Juve, with Organic Medical Growth OMG3 Inc. ("OMG3") for the exclusive distribution of Urban Juve products in Colombia and Brazil for a 5 year term. OMG3 plans to commence distribution of Urban Juve hemp-infused products in Colombia. The first products to be

offered will be Urban Juve's Face Moisturizer, Ritual Body Oil and signature Anti-Aging Serum.

2. Provide a general overview and discussion of the activities of management.

Please see Item 1 above.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

Please see Item 1 above.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

None.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

Please see Item 1 above.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

None.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

Please see Item 1 above.

8. Describe the acquisition of new customers or loss of customers.

Please see Item 1 above.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

Please see Item 1 above.

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

Please see Item 1 above.

11. Report on any labour disputes and resolutions of those disputes if applicable.

None.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

None.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

None.

14. Provide details of any securities issued and options or warrants granted.

| Security | Number Issued | Details of Issuance | Use of Proceeds ⁽¹⁾ |
|------------------|---------------|---|---|
| Special Warrants | 5,793,933 | August 7, 2019: 5,914,933 special warrants issued pursuant to a private placement at a price of \$0.30 per special warrant. Each special warrant is exercisable without further payment into one unit of the Issuer pursuant to the terms and conditions of the prospectus supplement filed on August 16, 2019. | Net proceeds of \$1,694,032 to be used as set out in the Prospectus Supplement. |
| Finder's Options | 268,160 | August 7, 2019: 268,160 finder's options issued pursuant to the special warrant private placement. Each finder's option is exercisable without further payment into one finder's unit warrant. | Not applicable |

| | | | |
|-----------------------|-----------|---|---|
| Units | 5,793,933 | August 21, 2019: 5,914,933 units issued pursuant to the conversion of the special warrants issued on August 7, 2019. Each unit consists of one common share and one common share purchase warrant exercisable at \$0.35 until August 7, 2021. | Not applicable |
| Finder's Unit Warrant | 268,160 | August 21, 2019: 268,160 finder's unit warrants issued pursuant to the conversion of the finder's options issued on August 7, 2019. Each finder's unit warrant is exercisable at a price of \$0.30 per finder's unit warrant into one unit of the Issuer. Each unit shall consist of one common share and one common share purchase warrant exercisable at \$0.35 until August 7, 2021. | Not applicable |
| Special Warrants | 1,707,332 | August 7, 2019: 1,707,332 special warrants issued pursuant to a private placement at a price of \$0.30 per special warrant. Each special warrant is exercisable without further payment into one unit of the Issuer pursuant to the terms and conditions of the prospectus supplement filed on August 16, 2019. | Net proceeds of \$492,130 to be used as set out in the Prospectus Supplement. |
| Finder's Options | 66,900 | August 7, 2019: 66,900 finder's options issued pursuant to the special warrant private placement. Each finder's option is exercisable without further payment into one finder's unit warrant. | Not applicable |

(1) State aggregate proceeds and intended allocation of proceeds.

15. Provide details of any loans to or by Related Persons.

None.

16. Provide details of any changes in directors, officers or committee members.

None.

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

On June 20, 2018, the Government of Canada held the final vote on Bill C-45, the Cannabis Act, in the Senate. The Cannabis Act passed in the Senate and received Royal Assent on June 21, 2018. The Cannabis Act came into force on October 17, 2018. recreational cannabis is now available to legal adults (aged 18 or 19 depending on the province or territory) for purchase, growth, or use in limited quantities. The Government of Canada is anticipated to pass legislation in late 2019 to approve and regulate the sale of Cannabis topical and edible products.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated September 1, 2019.

Penny White
Name of Director or Senior Officer

"Penny White"
Signature

Chief Executive Officer and
President
Official Capacity

| | | |
|--|---|--|
| Issuer Details Name of Issuer The Yield Growth Corp. | For Month End August 2019 | Date of Report YY/MM/DD 19/09/01 |
| Issuer Address Suite 200, 1238 Homer Street | | |
| City/Province/Postal Code Vancouver, British Columbia V6B 2Y5 | Issuer Fax No. N/A | Issuer Telephone No. 833.514.2677 |
| Contact Name Penny White | Contact Position President, CEO, and Director | Contact Telephone No. 833.514.2677 |
| Contact Email Address penny@yieldgrowth.com | Web Site Address www.yieldgrowth.com | |